drugset / Trial / NCT03413306

Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA

NCT03413306

RandomizedParallel-groupOpen-labelTreatment

Summary

The analysis of our own clinical data suggests that majority of the hematologic responses observed after the course of h-ATG/CsA is partial, and about 10% tend to have cyclosporine dependence. The aim of the current study is to improve the rate and the quality of hematologic response as well as to prevent delayed complications such as relapse and clonal progression by means of adding eltrombopag to standard immunosuppressive therapy

Timeline

Start
2016-12-10
Primary completion
2022-10-20
Completion
2022-10-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Eltrombopag Small molecule Oral
Background ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic
Background Cyclosporine Peptide